Tuesday - July 8, 2025
SECAUCUS, N.J., Sept. 7, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today released its 2022 Corporate Responsibility Report.
The report provides information on the company's strategy regarding environmental, social, and governance (ESG) issues which aligns with The Quest Way, the company's purpose, strategy and culture.
"Our approach to ESG helps us to deliver on our strategy and our purpose of working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President.
"This report highlights our strategies and initiatives in equity and health access, employee and community engagement, governance, and the environment. Quest is well-positioned to play an even more significant role in the evolving healthcare ecosystem, including through our investments in the areas of molecular genomics, oncology and consumer health. I'm proud of the work our team is doing to help create a healthier world, and excited about what lies ahead for us."
In 2022, Quest took an important step in its ESG strategy, establishing a set of goals based on priorities identified in its materiality assessment. The four pillars of the company's ESG strategy are: Governance and ethics; Equity and health access; Employee and community engagement; and Environmental sustainability.
"We're making good progress executing our ESG strategy, driving alignment, and embedding ESG throughout our operations to build long-term sustainable value for all of our stakeholders," said Sam Samad, Executive Vice President and Chief Financial Officer, who leads the company's ESG Leadership Council. "Realizing our purpose of helping to create a healthier world requires a team effort among our employees, partners and the communities we serve."
The report features key impact areas and highlights from 2022, including:
Click here to view the report on the Quest Diagnostics corporate website.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
Last Trade: | US$173.97 |
Daily Change: | -2.95 -1.67 |
Daily Volume: | 632,274 |
Market Cap: | US$19.420B |
June 10, 2025 April 22, 2025 April 09, 2025 April 02, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load